Valuation: Pasithea Therapeutics Corp.

Market Cap 14.51M 13.23M 12.24M 11.04M 20.8M 1.36B 21.62M 148M 58.42M 732M 54.44M 53.3M 2.31B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 14.51M 13.23M 12.24M 11.04M 20.8M 1.36B 21.62M 148M 58.42M 732M 54.44M 53.3M 2.31B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
89.9%
Yield 2026 *
-
Yield 2027 * -
11-14 Pasithea Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 CI
11-03 Pasithea Therapeutics Corp. Announces FDA Clearance Of IND For PAS-004 In Neurofibromatosis Type 1-Associated Cutaneous Neurofibromas CI
10-23 Pasithea Therapeutics Corp. Announces Positive PAS-004 Clinical Data From Phase 1 Advanced Cancer Study Presented At ESMO Congress 2026 CI
08-14 Pasithea Therapeutics Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
06-30 Pasithea Therapeutics Reports Positive Interim Phase 1 Advanced Cancer Study Data And Protocol Expansion CI
06-30 Pasithea Therapeutics Says Interim Phase 1 Data for PAS-004 Show Durable Clinical Activity MT
06-16 Pasithea Therapeutics Amends PAS-004 Trial to Add Higher Dose Levels, Extend Treatment MT
06-16 Pasithea Therapeutics Amends Clinical Study Protocol for Phase 1/1B Nf1 Clinical Trial CI
06-02 Pasithea Therapeutics Gets US FDA Orphan Drug Status for ALS Candidate MT
05-15 Pasithea Therapeutics Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
05-04 Pasithea Therapeutics Corp. Appoints Kartik Krishnan as Chief Medical Officer, Effective May 1, 2026 CI
04-20 Pasithea Therapeutics Corp Announces Grant of Rare Pediatric Disease Designation by FDA to Pas-004 for Treatment of Neurofibromatosis Type 1 CI
04-01 Pasithea Therapeutics Corp Announces Grant of Fast Track Designation by Fda to Pas-004 for Treatment of Neurofibromatosis Type 1 Associated Plexiform Neurofibromas Causing Significant Morbidity CI
1 day+13.75%
1 week-7.11%
Current month+33.50%
1 month+19.86%
3 months-0.68%
6 months-35.82%
Current year-61.69%
1 week 0.42
Extreme 0.41865
0.58
1 month 0.34
Extreme 0.3448
0.61
Current year 0.34
Extreme 0.3448
1.28
1 year 0.28
Extreme 0.281
2.06
3 years 0.28
Extreme 0.281
17.4
5 years 0.28
Extreme 0.281
170
10 years 0.28
Extreme 0.281
170
Manager TitleAgeSince
Chief Executive Officer 49 01/08/2020
Director of Finance/CFO 48 11/10/2022
Chief Tech/Sci/R&D Officer 55 01/05/2026
Director TitleAgeSince
Chairman 78 -
Director/Board Member 49 01/08/2020
Director/Board Member 49 01/04/2021
Date Insider Type Main position Quantity % Market Cap. Importance
5/1/26 A Free

Director

152,783 0.6126%
5/1/26 A Free

Director

152,783 0.6126%
5/1/26 A Free

Chief Technology Officer

1,129,323 4.5282%
Change 5-day change 1-year change 3-year change Capi.($)
+13.75%-7.11%-25.12%-92.31% 14.51M
-1.34%-4.12%+53.70%+68.83% 66.37B
+0.59%-1.83%+8.98%+90.68% 58.86B
+0.54%+0.45%+25.96%+86.62% 55.22B
-2.17%-3.84%+10.97%+114.95% 47.21B
+0.11%-6.15%+18.58%+25.51% 42.45B
-2.58%+2.22%+14.73%+41.28% 36.44B
-1.33%-11.28%+127.13%+637.74% 35.19B
-0.17%-1.83%+82.46%+57.48% 32.66B
-1.33%-0.42%-40.36%+388.38% 26.73B
Average +0.60%-3.46%+27.70%+141.92% 40B
Weighted average by Cap. -0.77%-2.92%+33.55%+143.09%

Financials

2026 *2027 *
Net sales - -
Net income - -
Net Debt - -
Projected Income Statement - Annual - Pasithea Therapeutics Corp.
Logo Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases. The Company is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and a number of oncology indications, among others. Its remaining two programs, PAS-001 and PAS-003, are in the earlier stages of development and are based on novel targets for the treatment of CNS disorders that it believes address limitations in the treatment paradigm of the indications it plans to address, which are amyotrophic lateral sclerosis (ALS) for its PAS-003 program, and schizophrenia for its PAS-001 program.
Employees
5
Date Price Change Volume
18/11/26 $0.4947 +13.91% 629,469
17/11/26 $0.4343 -13.14% 2,079,843
16/11/26 $0.5000 -4.21% 944,241
13/11/26 $0.5220 +0.40% 2,368,383
12/11/26 $0.5199 -2.27% 198,260
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.4343USD
Average target price
4.000USD
Spread / Average Target
+821.02%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Pasithea Therapeutics Corp.
  1. Stock Market
  2. Stocks
  3. KTTA Stock